PMID- 23685341
OWN - NLM
STAT- MEDLINE
DCOM- 20131113
LR  - 20161125
IS  - 1879-3169 (Electronic)
IS  - 0378-4274 (Linking)
VI  - 220
IP  - 3
DP  - 2013 Jul 18
TI  - Catechol estrogens induce proliferation and malignant transformation in prostate 
      epithelial cells.
PG  - 247-58
LID - S0378-4274(13)00202-6 [pii]
LID - 10.1016/j.toxlet.2013.05.002 [doi]
AB  - In the current study, the non-transformed prostatic epithelial cells (BPH-1) were 
      exposed to the catechol estrogens (CE) 2-hydroxyestradiol (2-OHE2) or 
      4-hydroxyestradiol (4-OHE2), or the parent hormone 17-beta-estradiol (E2) at an 
      equimolar concentration (1muM) for a period of 6 weeks. It was found that both 
      2-OHE2 and 4-OHE2 have more potent proliferation-enhancing effect than E2. 
      Exposure to 2-OHE2, 4-OHE2 or E2 resulted in a significant increase in the 
      protein abundance of cyclin D1 and c-myc. The treated cells exhibited a shift 
      toward the proliferative phase as indicated by FACScan. BPH-1 cells treated with 
      4-OHE2 showed increased abundance of estrogen receptor-alpha (ERalpha) and its downstream 
      IGF-1R. Reduced abundance of estrogen receptor-beta (ERbeta) and its downstream tumor 
      suppressor FOXO-1 were observed in cells exposed to E2, 2-OHE2 and, to a greater 
      extent, 4-OHE2. Comet assay revealed that CE, especially 4-OHE2, elicited 
      significant genotoxic effects as compared to E2. 4-OHE2 showed greater ability to 
      neoplastically transform BPH-1 cells as indicated by increased colony forming 
      capacity in soft agar and matrix invasion. In conclusion, in vitro exposure to CE 
      could neoplastically transform human prostatic epithelial cells. Further, 4-OHE2 
      is more carcinogenic to prostate epithelial cells than the parent hormone E2.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
FAU - Mosli, Hisham A
AU  - Mosli HA
AD  - Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, 
      Saudi Arabia.
FAU - Tolba, Mai F
AU  - Tolba MF
FAU - Al-Abd, Ahmed M
AU  - Al-Abd AM
FAU - Abdel-Naim, Ashraf B
AU  - Abdel-Naim AB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130515
PL  - Netherlands
TA  - Toxicol Lett
JT  - Toxicology letters
JID - 7709027
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Estrogens, Catechol)
RN  - 0 (FOXO1 protein, human)
RN  - 0 (Forkhead Box Protein O1)
RN  - 0 (Forkhead Transcription Factors)
RN  - 4TI98Z838E (Estradiol)
RN  - AYU2L67YUU (2-hydroxyestradiol)
RN  - C3ZO03450E (4-hydroxyestradiol)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
SB  - IM
MH  - Cell Cycle/drug effects
MH  - Cell Line
MH  - Cell Proliferation/drug effects
MH  - Cell Transformation, Neoplastic/*chemically induced/metabolism/pathology
MH  - Comet Assay
MH  - DNA Damage
MH  - Epithelial Cells/drug effects/pathology
MH  - Estradiol/*analogs & derivatives/pharmacology
MH  - Estrogen Receptor alpha/metabolism
MH  - Estrogen Receptor beta/metabolism
MH  - Estrogens, Catechol/*pharmacology
MH  - Flow Cytometry
MH  - Forkhead Box Protein O1
MH  - Forkhead Transcription Factors/metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Prostate/*drug effects/metabolism/pathology
MH  - Prostatic Neoplasms/*chemically induced/metabolism/pathology
MH  - Receptor, IGF Type 1/metabolism
EDAT- 2013/05/21 06:00
MHDA- 2013/11/14 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/01 00:00 [received]
PHST- 2013/05/03 00:00 [revised]
PHST- 2013/05/06 00:00 [accepted]
PHST- 2013/05/21 06:00 [entrez]
PHST- 2013/05/21 06:00 [pubmed]
PHST- 2013/11/14 06:00 [medline]
AID - S0378-4274(13)00202-6 [pii]
AID - 10.1016/j.toxlet.2013.05.002 [doi]
PST - ppublish
SO  - Toxicol Lett. 2013 Jul 18;220(3):247-58. doi: 10.1016/j.toxlet.2013.05.002. Epub 
      2013 May 15.